12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BA058-transdermal: Phase II started

Radius began a double-blind, placebo-controlled, international Phase II trial to compare once-daily 50, 100 and 150 µg BA058-TD vs. once-daily 80 µg subcutaneous BA058-Injection ( BA058-SC) for 6 months in about 240 postmenopausal women with osteoporosis. BA058-Injection is in Phase III...

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >